Adjuvant Immunotherapy With Toripalimab Following Curative-intent Ablation for Recurrent Hepatocarcinoma

NCT05240404 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

116

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Toripalimab
PROCEDURE: Thermal ablation

Sponsor

Xiangya Hospital of Central South University